Make REQUIP part of your long-term treatment strategy for Parkinson’s disease.
 |
As Initial Monotherapy
- May delay L-dopa use1
- Significantly reduces the risk of dyskinesia vs L-dopa1
- Maintains patients’ ADLs comparable to L-dopa1
As Adjunct Therapy
- Helps reduce or spare the need for additional L-dopa8
- Significantly reduces awake time spent "off"8
- Offers patients substantial improvement as measured by the CGI-I Scale8
With Progressive Dosing
- REQUIP provides progressive dosing to help meet individual patient needs
- Established safety and tolerability profile — used in clinical practice since 1997 in the United States
|
Next: Initial Therapy
